Community Update Roche: End of Year Community Letter
We are pleased to share the latest Community Letter issued by Roche, providing an update on their ongoing efforts in Spinal Muscular Atrophy (SMA) in 2024. The letter includes the latest developments on risdiplam and Roche’s SMA clinical development program.
Key highlights from the update include:
- Risdiplam approved in 100+ countries, reimbursed in 59, with expanded access for adults in Denmark.
- Final FIREFISH data confirmed sustained efficacy and safety in children with Type 1 SMA.
- New insights from SUNFISH, RAINBOWFISH, and tablet bioequivalence studies presented at major congresses.
- Published the “Care for Adults Living with SMA in Europe” report and supported SMA My Way podcasts and Global SMAdvocacy events.